<DOC>
	<DOCNO>NCT00723203</DOCNO>
	<brief_summary>RATIONALE : Panobinostat may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase II trial study side effect panobinostat see well work treat patient relapsed refractory acute lymphoblastic leukemia acute myeloid leukemia .</brief_summary>
	<brief_title>Panobinostat Treating Patients With Relapsed Refractory Acute Lymphoblastic Leukemia Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine antitumor activity panobinostat , term objective response rate , time progression , survival , patient relapse refractory acute lymphoblastic leukemia acute myeloid leukemia . - To assess toxicity panobinostat patient . Secondary - To perform correlative laboratory study assess change various protein may alter histone deacetylase inhibition therapy . OUTLINE : Patients receive oral panobinostat day 1 , 3 , 5 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients undergo peripheral blood bone marrow sample collection baseline day 28 course 1 correlative laboratory study . Samples analyze RT-PCR reactivation FANCG , FOXO3A , GADD45A , GADD45B , GADD45G , H2AX , TP73 . After completion study treatment , patient follow least 4 week . PROJECTED ACCRUAL : A total 74 patient ( 37 acute myeloid leukemia 37 acute lymphoblastic leukemia ) accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm acute myeloid leukemia acute lymphoblastic leukemia ( ALL ) Relapsed refractory disease Patients Philadelphia chromosomepositive ( Ph+ ) ALL refractory BCR/ABL inhibitor eligible Patients relapse prior autologous allogenic stem cell transplant eligible No active CNS disease PATIENT CHARACTERISTICS : ECOG performance status 02 Serum albumin ≥ 3 g/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( 5.0 time ULN transaminase elevation due leukemic involvement ) Bilirubin ≤ 1.5 time ULN Creatinine ≤ 1.5 time ULN creatinine clearance ≥ 50 mL/min Potassium ≥ low limit normal ( LLN ) Phosphorous ≥ LLN Serum total calcium ( correct serum albumin ) serum ionized calcium ≥ LLN Magnesium ≥ LLN Thyroid stimulate hormone free T4 normal ( thyroid hormone replacement therapy allow ) LVEF ≥ LLN MUGA ECHO No impaired cardiac function , include follow : QTc &gt; 450 msec Congenital long QT syndrome History sustain ventricular tachycardia History ventricular fibrillation torsades de pointes Bradycardia ( i.e. , heart rate &lt; 50 beat per minute ) Pacemaker allow provided heart rate ≥ 50 beat per minute Myocardial infarction unstable angina within past 6 month New York Heart Association class IIIIV congestive heart failure Right bundle branch block leave anterior hemiblock ( bifascicular block ) No uncontrolled hypertension No unresolved diarrhea &gt; CTCAE grade 1 No impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption oral panobinostat Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublebarrier contraception 3 month completion study treatment No primary malignancy within past 5 year , curatively treat carcinoma situ cervix basal cell squamous cell carcinoma skin No HIV hepatitis C positivity No concurrent severe and/or uncontrolled medical condition No significant history noncompliance medical regimen inability give reliable inform consent PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) radiotherapy More 4 week since prior valproic acid No prior treatment histone deacetylase inhibitor No concurrent medication may cause QTc prolongation induce torsades de point No concurrent CYP3A4 inhibitors No concurrent grapefruit , grapefruit juice , Seville ( sour ) oranges No concurrent radiotherapy No concurrent anticancer therapy investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>